GISSI-3 - EFFECTS OF LISINOPRIL AND TRANSDERMAL GLYCERYL TRINITRATE SINGLY AND TOGETHER ON 6-WEEK MORTALITY AND VENTRICULAR-FUNCTION AFTER ACUTE MYOCARDIAL-INFARCTION
C. Devita et al., GISSI-3 - EFFECTS OF LISINOPRIL AND TRANSDERMAL GLYCERYL TRINITRATE SINGLY AND TOGETHER ON 6-WEEK MORTALITY AND VENTRICULAR-FUNCTION AFTER ACUTE MYOCARDIAL-INFARCTION, Lancet, 343(8906), 1994, pp. 1115-1122
GISSI-3 is a multicentre randomised clinical trial to assess the effic
acy of lisinopril, transdermal glyceryl trinitrate (GTN), and their co
mbination in improving survival and ventricular function after acute m
yocardial infarction (AMI). Between June, 1991, and July, 1993, 19 394
patients were randomised from 200 coronary care units in Italy. Eligi
ble patients presented within 24 h of symptom onset and had no clear i
ndications for or against the study treatments. In a factorial design
patients were randomly assigned 6 weeks of oral lisinopril (5 mg initi
al dose and then 10 mg daily) or open control as well as nitrates (int
ravenous for the first 24 h followed by transdermal GTN 10 mg daily) o
r open control. Complete clinical data and 6-week follow-up were avail
able for 18 895 (97.4%) patients randomised. Two-dimensional echocardi
ographic data were available for 14 209 patients. Overall 6-week morta
lity was 6.7%. Lisinopril, started within 24 h from AMI symptoms, prod
uced significant reductions in overall mortality (odds ratio 0.88 [95%
CI 0.79-0.99]) and in the combined outcome measure of mortality and s
evere ventricular dysfunction (0.90 [0.84-0.98]). In the same trial th
e systematic administration of transdermal GTN did not show any indepe
ndent effect on the same outcome measures (0.94 [0.84-1.05] and 0.94 [
0.87-1.02]). Systematic combined administration of lisinopril and GTN
also produced significant reductions in overall mortality (0.83 [0.70-
0.97]) and in the combined endpoint (0.85 [0.76-0.94]). The favourable
effect of lisinopril alone or with GTN was clear also in the predefin
ed high-risk populations (elderly patients and women) for the combined
endpoint. These findings were obtained in a population intensively ex
posed to recommended treatments (thrombolysis 72%, beta-blockade 31%,
and aspirin 84%); non-protocol treatment with angiotensin-converting-e
nzyme inhibitors and nitrates was allowed for specific clinical indica
tions. No excess of unfavourable clinically relevant events in the tre
ated groups was reported.